Date: 2016-05-12
Type of information: Resignation
Compound:
Company: Oxford Biomedica (UK)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease:
Details: * On May 12, 2016, Oxford BioMedica announced that Dr Paul Blake will leave the Group when his current contract expires at the end of August 2016. Dr Blake was appointed to Oxford BioMedica's Board as a non-executive Director in January 2010 and subsequently he became Chief Development Officer in September 2014.
Financial terms:
Latest news:
